Anti-IL-36 antibodies and methods of use thereof
Assignee23andMe, Inc.
InventorsChingwei Vivian Lee, Germaine Fuh-Kelly, Louise Scharf, Tina Thai, Ashka Bharat Patel, Shashank Bharill, Erik Edward Karrer
Life of this patent
Estimating the term…
Abstract
The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36α, IL-36β, and/or IL-36γ, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.
Claims23
An anti-IL-36 antibody comprising:
- (i) a light chain variable domain (VL) comprising a first light chain hypervariable region (HVR-L1), a second light chain hypervariable region (HVR-L2), and a third light chain hypervariable region (HVR-L3) and (ii) a heavy chain variable domain (VH) comprising a first heavy chain hypervariable region (HVR-H1), a second heavy chain hypervariable region (HVR-H2), and a third heavy chain hypervariable region (HVR-H3);
- wherein:
- HVR-L1 comprises the amino acid sequence of SEQ ID NO:
- 18, HVR-L2 comprises the amino acid sequence of SEQ ID NO:
- 19, HVR-L3 comprises the amino acid sequence of SEQ ID NO:
- 20, HVR-H1 comprises the amino acid sequence of SEQ ID NO:
- 158, HVR-H2 comprises the amino acid sequence of SEQ ID NO:
- 159, and HVR-H3 comprises the amino acid sequence of SEQ ID NO:
- 160;
- HVR-L1 comprises the amino acid sequence of SEQ ID NO:
- 18, HVR-L2 comprises the amino acid sequence of SEQ ID NO:
- 19, HVR-L3 comprises the amino acid sequence of SEQ ID NO:
- 20, HVR-H1 comprises the amino acid sequence of SEQ ID NO:
- 106, HVR-H2 comprises the amino acid sequence of SEQ ID NO:
- 107, and HVR-H3 comprises the amino acid sequence of SEQ ID NO:
- 108;
- HVR-L1 comprises the amino acid sequence of SEQ ID NO:
- 34, HVR-L2 comprises the amino acid sequence of SEQ ID NO:
- 35, HVR-L3 comprises the amino acid sequence of SEQ ID NO:
- 36, HVR-H1 comprises the amino acid sequence of SEQ ID NO:
- 66, HVR-H2 comprises the amino acid sequence of SEQ ID NO:
- 67, and HVR-H3 comprises the amino acid sequence of SEQ ID NO:
- 68, or
- HVR-L1 comprises the amino acid sequence of SEQ ID NO:
- 18, HVR-L2 comprises the amino acid sequence of SEQ ID NO:
- 19, HVR-L3 comprises the amino acid sequence of SEQ ID NO:
- 20, HVR-H1 comprises the amino acid sequence of SEQ ID NO:
- 50, HVR-H2 comprises the amino acid sequence of SEQ ID NO:
- 51, and HVR-H3 comprises the amino acid sequence of SEQ ID NO:
- 52.
A composition comprising an antibody of claim and a pharmaceutically acceptable carrier.
A multispecific antibody comprising a pair of light chains (LC) wherein each LC comprises the sequence of SEQ ID NO:
- 169 and a first and second heavy chain (HC), wherein the first HC comprises the sequence of SEQ ID NO:
- 235 and the second HC comprises SEQ ID NO:
- 192.
An anti-IL-36 antibody comprising:
- a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:
- 77 and a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:
- 157;
- a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:
- 77 and a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:
- 105;
- a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:
- 78 and a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:
- 80;
- or
- a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:
- 77 and a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:
- 79.
An anti-IL-36 antibody comprising:
- a light chain comprising the amino acid sequence of SEQ ID NO:
- 169 and a heavy chain comprising the amino acid sequence of a sequence selected from the group consisting of SEQ ID NOs:
- 191, 192, 193, 203, 204, 205, 233, 234, and 235;
- or
- a light chain comprising the amino acid sequence of SEQ ID NO:
- 242 and a heavy chain comprising the amino acid sequence of sequence selected from SEQ ID NOs:
- 170, 171, and 172.
Dependencies are inferred from the claim text.